Literature DB >> 25953611

In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.

Rodrigo Liberal1,2, Charlotte R Grant1, Beth S Holder1, John Cardone1, Marc Martinez-Llordella1, Yun Ma1, Michael A Heneghan1, Giorgina Mieli-Vergani1,3, Diego Vergani1, Maria Serena Longhi1.   

Abstract

UNLABELLED: Defective immune regulation plays a permissive role enabling effector cells to initiate and perpetuate tissue damage, eventually resulting in autoimmune disease. Numerical and functional regulatory T-cell (Treg) impairment has been previously reported in autoimmune liver disease (AILD; including autoimmune hepatitis and autoimmune sclerosing cholangitis ASC). However, in these early reports, Tregs were phenotypically defined as CD4(+) CD25(+) or CD4(+) CD25(high) cells. In the current study, we reexamined phenotypic and functional properties of Tregs by adopting a more refined definition of these cells that also includes negativity or low level of expression of CD127. We studied 43 AILD patients and 22 healthy subjects (HSs) and found that CD4(+) CD25(+) CD127(-) Tregs were decreased in the former. This decrease was more marked in patients with active disease than in those in remission. In AILD, Treg frequencies correlated inversely with parameters of disease activity and were not affected by immunosuppressive treatment. We also document, for the first time, that, in AILD, bona-fide Tregs produce less interleukin (IL)-10 and are impaired in their ability to suppress CD4(+) CD25(-) target cell proliferation, a feature that in HSs, but not in AILDs, is dependent, at least in part, on IL-10 secretion. Decreased IL-10 production by Tregs in AILD is linked to poor responsiveness to IL-2 and phospho signal transducer and activator of transcription 5 up-regulation.
CONCLUSION: Tregs are numerically impaired in AILD, this impairment being more prominent during active disease. Notably, defective IL-10 production, resulting from low Treg responsiveness to IL-2, contributes to Treg functional impairment.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953611     DOI: 10.1002/hep.27884

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Patients with CD3G mutations reveal a role for human CD3γ in Treg diversity and suppressive function.

Authors:  Jared H Rowe; Ottavia M Delmonte; Sevgi Keles; Brian D Stadinski; Adam K Dobbs; Lauren A Henderson; Yasuhiro Yamazaki; Luis M Allende; Francisco A Bonilla; Luis I Gonzalez-Granado; Seyma Celikbilek Celik; Sukru N Guner; Hasan Kapakli; Christina Yee; Sung-Yun Pai; Eric S Huseby; Ismail Reisli; Jose R Regueiro; Luigi D Notarangelo
Journal:  Blood       Date:  2018-04-13       Impact factor: 22.113

2.  Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.

Authors:  Xiufang Weng; Ying He; Lavanya Visvabharathy; Chia-Min Liao; Xiaosheng Tan; Arjun Balakumar; Chyung-Ru Wang
Journal:  J Hepatol       Date:  2017-07-14       Impact factor: 25.083

Review 3.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

4.  Interleukin-10 Modulation of Virus Clearance and Disease in Mice with Alphaviral Encephalomyelitis.

Authors:  Nina M Martin; Diane E Griffin
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 5.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

6.  Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis.

Authors:  C R Grant; B S Holder; R Liberal; M A Heneghan; Y Ma; G Mieli-Vergani; D Vergani; M S Longhi
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

7.  Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.

Authors:  Rodrigo Liberal; Charlotte R Grant; Muhammed Yuksel; Jonathon Graham; Alireza Kalbasi; Yun Ma; Michael A Heneghan; Giorgina Mieli-Vergani; Diego Vergani; Maria Serena Longhi
Journal:  Hepatology       Date:  2017-10-03       Impact factor: 17.425

Review 8.  Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2021-04-09       Impact factor: 3.199

Review 9.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

10.  Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome.

Authors:  Yi Jiang; Bing-Hong Xu; Brandon Rodgers; Nikolaos Pyrsopoulos
Journal:  J Clin Transl Hepatol       Date:  2021-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.